Improved cyclization conditions to prepare 6-substituted pyrazolo[1,5-a]pyridines and pyrazolo[1,5-a]pyrazines using catalytic Ag(I) and Au(III) salts. John F. Braganza, et. al. Tetrahedron Letters, 2015, 56(42), pp. 5757-5760. Development of a Scalable Synthesis of 4-Aminopyrimidin-5-ol, a Versatile Intermediate. Phuong T. Le, et. al. Organic Process Research and Development, 2015, 19(6), pp.639-645.
About WuXi AppTec
This author has yet to write their bio.Meanwhile lets just say that we are proud WuXi AppTec contributed a whooping 42 entries.
Entries by WuXi AppTec
Medicinal Chemistry Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. T L Lasho et. al. Blood Cancer Journal 2015 5(e275). A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products. A. Estvez-Braun, et. al.,Clinical Translational Oncology. 2015, […]
WuXi News Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility Read full article here WuXi and Lilly Collaborate to Develop Novel Therapeutics in China Read full article here WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan Read full article here Congratulations to Novira Therapeutics for […]
UPCOMING: WuXi Representatives Visit Israel for EFMC-ASMC’15 Members of WuXi’s small molecule drug discovery platform (International Discovery Service Unit – IDSU) will be attending the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry from November 15-18 to meet with Israeli clients and colleagues. WuXi brings world class capability and capacity through […]
WuXi News WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan Read full article here WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan Read full article here WuXi Boston Welcomes Valdas Jurkauskas to Join the STA Team: An Interview with Valdas Jurkauskas, Executive Director, Technical Operations, […]
WuXi News WuXi NextCODE in Bloomberg on Ending a 30-year Diagnostic Odyssey in 3 Weeks Read full article here WuXi NextCODE Featured in Nature as the Innovative Engine of Population-scale Precision Medicine at Genomics England and Beyond Read full article here WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan Read full […]
WuXi News Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai Read full article here WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan Read full article here WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan Read full article here […]
Meet WuXi’s Israel Partner: An Interview with Ran Nussbaum, Co-Founder and Managing Partner of Pontifax Read full interview here Wuxi City Mayor Visits WuXi’s Israel Office The Wuxi government delegation visited Israel last week exploring ways to promote economic transformation for Wuxi city through developing advanced technologies and cultivating potential collaborations between Israel and Wuxi companies. Dana Yarden of WuXi’s Israel Office had […]
We are pleased to share with you that our partner and WuXi Venture Fund portfolio company Novira Therapeutics has agreed to be acquired by Johnson & Johnson. Novira’s lead compound, NVR 3-778, is a small-molecule, direct-acting antiviral for oral administration in patients with hepatitis B virus (HBV). The compound inhibits the HBV core or […]
Welcome Message from Steve Yang Welcome to the inaugural IDSU newsletter! As the new head of the International Discovery Services Unit (IDSU), I am proud to introduce our quarterly newsletter, bringing you the latest in medicinal chemistry and small molecule news, research, and events. For over a decade, WuXi AppTec has built an open […]